Raymond James Financial
IPSC icon

Raymond James Financial’s Century Therapeutics IPSC Stock Holding History

Raymond James Financial’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$156K Hold
91,323
– – ﹤0.01% 5143
2026
Q2 		$224K Hold
91,323
– – ﹤0.01% 4989
2026
Q1 		$206K Hold
91,323
– – ﹤0.01% 4872
2025
Q4 		$90.8K Hold
91,323
– – ﹤0.01% 4945
2025
Q3 		$45.5K Hold
91,323
– – ﹤0.01% 4834
2025
Q2 		$51K Buy
+91,323
New +$49K ﹤0.01% 5174

Other funds holding IPSC

Versant Venture Management
Versant Venture Management San Francisco, California $109M AUM 43.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Raymond James Financial's IPSC Position: Q3 2026 in Review

Raymond James Financial held its Century Therapeutics (IPSC) position steady in Q3 2026 at 91,323 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #5143.

Raymond James Financial first reported a position in IPSC in Q2 2025 and has held it in 6 quarters since. The position peaked at $224K in Q2 2026. 58 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.

  • Raymond James Financial held 91,323 shares of Century Therapeutics worth $156K as of Q3 2026.
  • Raymond James Financial left its Century Therapeutics share count unchanged in Q3 2026.
  • Century Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #5143 holding.
  • Raymond James Financial first reported a position in Century Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Raymond James Financial's Century Therapeutics position peaked at $224K in Q2 2026.
  • 58 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.